Roche Holding - Half-year 2026 results date and technical picture ahead
18.06.2026 - 13:16:41 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 11:10 UTC. Details in the imprint.
Roche Holding (CH0012032048) is preparing for a key earnings milestone with its half-year 2026 results scheduled for July 23, 2026, according to the company’s investor relations calendar. Roche investor events overview The date anchors expectations as investors also watch the current technical setup of the Swiss pharma group’s shares.
All news and key data on Roche Holding stock
The Roche calendar, current price data and archived announcements offer additional context for the upcoming half-year figures and the stock’s market position.
What Roche has scheduled next
Roche’s investor website lists the Half Year Results 2026 as a virtual event on July 23, 2026, following participation at the J.P. Morgan European Healthcare Forum in June. Roche investor events overview The half-year release will update the market on the performance of its pharmaceuticals and diagnostics divisions.
The event sits in a busy calendar for global healthcare investors, with large peers also reporting around late July. For Roche, the date will provide a reference point for guidance, pipeline progress and integration of recent product launches.
How the chart looks this Thursday
On the Swiss exchange, Roche participation certificates recently traded in a range around the mid-CHF 320s, after opening near CHF 324.70 and moving between CHF 324.00 and CHF 329.40 in today’s session, according to market data. Intraday quote data for Roche participation certificates That leaves the shares modestly above recent short-term support levels seen earlier in the month.
Against this backdrop, the technical picture appears balanced, with no extreme volatility and day-to-day moves remaining contained within a relatively narrow trading band. For chart watchers, the behavior around these levels into the July earnings date will be an important gauge of sentiment.
How Roche makes its money
Roche generates most of its revenue from prescription medicines in oncology, immunology and neuroscience, complemented by a large diagnostics franchise spanning centralized lab tests and point-of-care systems. Roche Annual Report 2023 Key therapies include cancer drugs and treatments for multiple sclerosis, supported by a broad portfolio of diagnostic assays.
Where the stock trades today
The shares of Roche Holding (CH0012032048) trade on SIX Swiss Exchange at CHF 327.00 as of 06/18/2026, 10:55 CET.
Key facts on Roche Holding stock
- Company: Roche Holding AG
- ISIN: CH0012032048
- WKN: 851311
- Ticker: ROG
- Venue: SIX Swiss Exchange
- Price (as of 06/18/2026, 10:55 CET): 327.00 CHF
- Market cap: 280,000,000,000 CHF (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: SMI, Stoxx Europe 600
- Next earnings date: 07/23/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
